GlassScriptPhysician profile
John M Palmer
NPI 1063510691
$418,584.84
in general payments reported to CMS, 2019-2025
23 companies · $3,757 in 2025
The $3,757 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $100K · 2021: $84K · 2022: $90K · 2023: $10K · 2024: $8,066 · 2025: $3,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,480 · Food and Beverage: $2,643 · Travel and Lodging: $1,534 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,171.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,480.00 |
| Food and Beverage | $2,642.76 |
| Travel and Lodging | $1,533.61 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $146,985.75 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $91,469.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $64,169.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $36,334.41 | 2019-2022 | |
| Dexcom, INC. | $26,714.13 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,143.45 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $20,511.39 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,220.70 | 2022-2023 | |
| Medtronic, INC. | $1,785.55 | 2021-2025 | Minimed 780g, Minimed 770g, Abre |
| Medtronic Minimed, INC. | $488.32 | 2019-2020 | |
| Abbott Laboratories | $388.56 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $80.32 | 2024-2025 | Tepezza, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $67.59 | 2025 | |
| Ascendis Pharma Endocrinology INC | $42.31 | 2025 | Skytrofa |
| Nevro Corp. | $37.91 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.84 | 2025 | |
| Janssen Scientific Affairs, LLC | $26.87 | 2019 | |
| Becton, Dickinson and Company | $24.61 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $15.02 | 2025 | Imcivree |
| Genzyme Corporation | $13.38 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Clarus Therapeutics INC. | $11.28 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $10.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.